GeLongHui September 19th | jiangsu hengrui pharmaceuticals (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biomedical Pharmaceuticals Co., Ltd., has received the "Acceptance Notice" issued by the National Medical Products Administration. The company's Rulafup-α injection (SHR-1701) has been accepted for drug marketing authorization application by the National Medical Products Administration, with indications for: the combination of this product with fluoropyrimidine and platinum-based drugs for the first-line treatment of locally advanced unresectable, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma.
恒瑞医药(600276.SH)：瑞拉芙普-α注射液药品上市许可申请获受理
Jiangsu Hengrui Pharmaceuticals (600276.SH): The pharmaceutical product application for marketing approval of Rurafup-α injection has been accepted.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.